VIR News and Press, Vir Biotechnology Inc. From 01/27/26

Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks Canada NewsWire Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Jan. 27, 2026 /CNW/ -- Equity-Insider.com   News Commentary – The global oncology therapy market is ...

2026-01-15 02:25:58 ET Vir Biotechnology, Inc. (VIR) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 6:45 PM EST... Read the full article on Seeking Alpha For further details see: Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Con...

2026-01-13 10:15:03 ET Benchmark analyst issues BUY recommendation for VIR on January 13, 2026 03:42PM ET. The previous analyst recommendation was Buy. VIR was trading at $6.045 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...

2026-01-12 08:14:58 ET More on Vir Biotechnology Vir Biotechnology, Inc. 2025 Q3 - Results - Earnings Call Presentation Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript Vir Biotechnology issues license to Norgine to market hepatitis D candidate ...

– Positive, updated Phase 2 SOLSTICE data showed combination of tobevibart and elebsiran is well tolerated and achieved undetectable HDV RNA in 88% of chronic hepatitis delta participants evaluable at 96 Weeks of treatment – New Phase 1 data from PSMA-targeted PRO-XTEN ...

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 at 3:45 p.m. PT in San Francisco, California. A live webcast of the prese...

2025-12-16 17:02:27 ET More on Vir Biotechnology Vir Biotechnology, Inc. 2025 Q3 - Results - Earnings Call Presentation Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript Vir Biotechnology outlines accelerated hepatitis delta milestones and cash runway in...

– Vir Biotechnology to receive EUR 55 million initial reimbursement payment upon closing, and up to EUR 495 million in clinical, regulatory and sales milestones, along with tiered, mid-teen to high-twenties percent royalties on net sales – Companies to share clinical devel...

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida. A live w...

SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination well-tolerated: No grade 3 or higher treatment-related adverse events and no treatment-related discont...